ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,136.99
0.42%
Dow Jones
43,297.03
0.91%
Gold vs US Dollar
2,625.49
0.27%
Brent Oil
73.265
-0.03%
Bitcoin
98,024.65
-1.29%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Roivant Sciences Ltd (ROIV)

  7. Roivant Sciences Ltd (ROIV) News

Roivant Sciences (ROIV)

Roivant Sciences Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ROIV
DateTimeSourceHeadlineSymbolCompany
03/12/202412:00GlobeNewswire Inc.Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisNASDAQ:ROIVRoivant Sciences Ltd
03/12/202412:00GlobeNewswire Inc.Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisNASDAQ:ROIVRoivant Sciences Ltd
12/11/202412:00GlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
29/10/202420:35GlobeNewswire Inc.Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024NASDAQ:ROIVRoivant Sciences Ltd
28/10/202413:25GlobeNewswire Inc.Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NASDAQ:ROIVRoivant Sciences Ltd
18/09/202411:30GlobeNewswire Inc.Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NASDAQ:ROIVRoivant Sciences Ltd
10/09/202410:30GlobeNewswire Inc.Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) ActivatorNASDAQ:ROIVRoivant Sciences Ltd
10/09/202410:30GlobeNewswire Inc.Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society CongressNASDAQ:ROIVRoivant Sciences Ltd
09/09/202411:00GlobeNewswire Inc.Roivant Provides Update on Graves’ Disease Development ProgramNASDAQ:ROIVRoivant Sciences Ltd
08/08/202411:00GlobeNewswire Inc.Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
25/07/202420:05GlobeNewswire Inc.Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024NASDAQ:ROIVRoivant Sciences Ltd
31/05/202401:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
30/05/202420:46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ROIVRoivant Sciences Ltd
30/05/202411:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202411:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202411:00GlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
23/05/202401:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202401:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202401:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
16/05/202420:05GlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024NASDAQ:ROIVRoivant Sciences Ltd
02/04/202411:00GlobeNewswire Inc.Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionNASDAQ:ROIVRoivant Sciences Ltd
26/03/202422:22PR Newswire (US)Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600NASDAQ:ROIVRoivant Sciences Ltd
13/02/202412:00GlobeNewswire Inc.Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
30/01/202421:05GlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024NASDAQ:ROIVRoivant Sciences Ltd
20/12/202321:30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:ROIVRoivant Sciences Ltd
14/12/202314:00GlobeNewswire Inc.Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel DiseaseNASDAQ:ROIVRoivant Sciences Ltd
28/11/202312:00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:ROIVRoivant Sciences Ltd
27/11/202313:00GlobeNewswire Inc.Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus ErythematosusNASDAQ:ROIVRoivant Sciences Ltd
13/11/202312:00GlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
10/11/202313:00GlobeNewswire Inc.Roivant Announces Appointment of Mayukh Sukhatme to Its Board of DirectorsNASDAQ:ROIVRoivant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:ROIV

Your Recent History

LSE
ULT
Ultrasis
LSE
EDEN
Eden Research
LSE
SEA
Seascape Energy Asia
LSE
JUS
Jupiter Us Smaller Compa...
LSE
SRSP
Sirius Petroleum
LSE
PSN
Persimmon
LSE
ALGW
Alpha Growth
LSE
SYME
Supply@me Capital
LSE
AMD
Aim Distribution Trust
LSE
CAML
Central Asia Metals
LSE
CYN
Cqs Natural Resources Gr...
LSE
FAR
Ferro-alloy Resources
LSE
KOS
Kosmos Energy
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads